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Long QT syndrome (LQTS), a rare inheritable arrhythmia ﬁrst
described by Romano andWard et al. in the 1960s, is characterized by
the prolongation of the QT interval on surface ECGs and an increased
risk of potentially fatal ventricular arrhythmias, especially torsade de
pointes [1]. In 1995, after years of extensive clinical investigation and
linkage analysis, several research groups, including Keating et al.,
successfully identiﬁed three distinct LQTS phenotypes (LQT1, LQT2,
and LQT3) associated with mutations in genes encoding plasma
membrane ion channels (KCNQ1, KCNH2, and SCN5A, respectively)
[2–4]. These seminal studies motivated further extensive genetic
screening in LQTS patients using a candidate gene approach and
functional analyses of the mutant genes. These efforts provided
evidence that ion channel genes represent the genetic basis for
several other arrhythmogenic syndromes that occur in the structu-
rally intact heart, often referred to as idiopathic ventricular ﬁbrilla-
tion. At present, 13 genes responsible for LQTS have been identiﬁed.
Approximately 90% of the genotyped LQTS subjects belong to the
three major subtypes (LQT1-3) [5] in which numbers of distinct
genotype-speciﬁc clinical characteristics have been demonstrated,
including T-wave morphology [6], triggers for cardiac events [7],
response to the epinephrine provocation test [8] and drug therapy [9].
Genetic testing for known arrhythmia susceptibility genes has
become the standard-of-care for a number of disorders, including
LQTS. Considering the remarkable progress of research in this area,
there is no doubt that 1995 was the year in which genetic technol-
ogies experienced a paradigm shift with respect to both the under-
standing and clinical management of inherited arrhythmias. However,
it should be noted that despite the rapid progress in understanding
the genetic basis, the etiology still remains unknown in approxi-
mately 20% of LQTS conditions [10]. Therefore, additional studies are
needed to reveal the missing heritable factors associated with these
syndromes.
Traditionally, DNA sequence information has been elucidated
using Sanger sequencing, but this method is limited by the amount
of DNA that can be processed at a given time and by the read
length (average 800 base pairs). Although the Human Genome
Project completed the sequencing of the entire human genome in
2001 using Sanger sequencing, it took 13 years of effort at an
estimated cost of $2.7 billion. Now, next-generation sequencing
(NGS), a revolutionary new genetic technology, has enabled whole
genomes to be sequenced over a period of a few days at projected
costs of less than $10,000. This technology involves massively
parallel sequencing of clonally ampliﬁed or single DNA molecules
that are spatially separated in a ﬂow cell.
To date, the genes responsible for disease in more than 3000
Mendelian disorders have yet to be identiﬁed. NGS opens up
exciting new possibilities of discovering the genes associated with
these monogenic disorders. Classical strategies involve linkage
analysis in families with known shared genetic heritage by
identifying candidate genomic regions encompassing the gene
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with the causative mutation. After narrowing the interval with
additional families/probands, a candidate gene approach or an
approach of systematically sequencing the genes located within
the interval can be implemented. Genome-wide association stu-
dies (GWAS), which use single nucleotide polymorphisms (SNPs),
can signiﬁcantly expedite the linkage analysis by narrowing the
regions of interest for further directed sequencing. GWAS have
been applied in the cardiac electrophysiological ﬁeld and over 100
traits have been identiﬁed for common diseases such as atrial
ﬁbrillation, or ECG parameters such as PR, QT, and RR intervals and
QRS durations [11]. These conventional approaches are costly and
time-consuming, and their success in identifying the causative
genetic variants has been variable, mainly because of the small
numbers of affected individuals for a given Mendelian disease and
also possibly due to locus heterogeneity. However, a recent multi-
center GWAS study involving our group has shown that common
genetic variation can have a strong impact on the predisposition of
rare diseases such as Brugada syndrome [12].
Deep resequencing of all human genes for the discovery of
allelic variants could potentially identify genes whose dysfunction
underlies any given rare monogenic disease when a shared genetic
heritage is not readily available. Protein-coding exons represent
only approximately 1% of the entire 30-Mbp human genome but
are estimated to harbor approximately 85% of the mutations that
cause largely govern the expression of disease-related traits.
Indeed, most Mendelian disorders are thought to be attributable
to exonic mutations or splice-site mutations that alter the amino
acid sequence of the affected gene. Therefore, whole exon sequen-
cing (WES) (or exome sequencing) using NGS platforms will allow
vastly higher sequence coverage with considerably less raw
sequence and lower cost than whole genome sequencing. Since
its ﬁrst application in 2008, a number of previously unidentiﬁed
monogenic traits have been discovered using WES techniques
[13–15]. These results have been achieved frequently using a
limited number of patients with genetic defects in both autosomal
dominant [14] and recessive [15] disorders. The implementation of
NGS technology in cardiology is expected to bring a second
paradigm shift in how clinical cardiologists diagnose patients
and how researchers investigate both common and rare disorders.
Potentially, all causative variants and genes and their relation to
phenotypes in Mendelian disorders will be uncovered in the very
near future. Such technologies should also enable us to identify all
the variants in an individual's personal genome and, in particular,
to highlight clinically relevant alleles. Whole genome sequencing
is expected to produce a major shift in clinical practice in terms of
diagnosis and understanding of cardiovascular diseases, which will
ultimately enable personalized medicine based on an individual's
genome.
Crotti et al. recently identiﬁed two novel disease-causing genes
responsible for sudden unexplained death syndrome using WES
[16]. They studied two unrelated infants with recurrent cardiac
arrest and dramatically prolonged QTc intervals who were both
born to healthy parents. The probands were conﬁrmed in advance
to be negative for mutations in major LQTS genes KCNQ1, KCNH2,
SCN5A, KCNE1, and KCNE2. Applying WES to the two unrelated
probands and their healthy parents, they searched for de novo
genetic variants and found de novo mutations in either CALM1 or
CALM2, which encode calmodulin. To validate these WES results,
they performed follow-up genetic screening of the calmodulin
genes (CALM1, CALM2, and CALM3) on an independent cohort of 82
subjects who had congenital LQTS without a known genetic cause.
They identiﬁed two individuals from this cohort who also dis-
played variations in calmodulin; one individual harbored the same
mutation in CALM1 as that seen in proband 1, and the other
individual had a novel missense mutation in CALM1. The muta-
tions altered residues in, or adjacent to, critical calcium binding
loops in the calmodulin carboxyl-terminal domain. To determine
the functional consequences of calmodulin mutations, they mea-
sured the Ca2þ binding activities of the recombinant calmodulin
proteins in bacteria and conﬁrmed that three mutations have
signiﬁcantly reduced Ca2þ afﬁnity in the C domain.
The discovery of pathological variants in calmodulin has raised
a variety of interesting and novel research questions. First, the
observations by Crotti et al. illustrate the genotypic and pheno-
typic heterogeneity of calmodulin mutations. The mutant carriers
in the study by Crotti et al. presented with early-onset life-
threatening cardiac arrhythmias, prolonged QT intervals, and
neurodevelopmental delay. Studies by other groups showed that
mutations in CALM1 may be linked to catecholaminergic poly-
morphic ventricular tachycardia with [17] or without [18] pro-
longed QT intervals. Furthermore, although the three calmodulin
genes (CALM1, CALM2, and CALM3) are dispersed in the genome
and encode identical calmodulin polypeptides, the phenotype
variants exhibit considerable differences in severity of clinical
phenotype. This phenotypic variability may suggest that the
cellular distribution, gene dosage, or function of each calmodulin
gene may not be equivalent. Although the authors did not address
this issue, it will be intriguing to identify the molecular targets of
calmodulin in the heart that underlie the action potential prolon-
gation, as well as the predisposition to lethal arrhythmias. Clearly,
more extensive experimental work, including studies of geneti-
cally engineered animals, is required to address these questions, to
reﬁne current disease classiﬁcations, and to learn more about the
genomic origins of these and other diseases.
NGS technologies have the potential to uncover the hidden
etiologies of many diseases; however, such technologies are a
“double edged sword” because investigators leading clinical
sequencing efforts may face serious ethical issues. They may
unintentionally ﬁnd a life-threatening genetic variation in a
patient who is unrelated to the project, or they may question
the decision whether they should provide the genetic information
to family members in the event that a patient dies.
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